Taisho Pharmaceutical Co., Ltd.

Meiji Seika Kaisha, Ltd.

Meiji Seika Pharma Co., Ltd.

Tomohiro Ozawa

Masato Kashimura

Eiki Shitara

Tomohiro Sugimoto

Tomoaki Miura

Kenichi Kanemoto

Kanako Yamamoto

Jun Kurosaka

Ken Chikauchi

Naoki Sasamoto

Haruhisa Ogita

Dai Kubota

Madoka Kawamura

Akira Manaka

A novel 10a-azalide compound crosslinked at the 10a- and 12-positions, which is represented by the following formula, and is effective on even, or erythromycin resistant bacteria (e.g., resistant pneumococci and streptococci). 

10a-Azalide compound crosslinked at 10a- and 12-positions

[Object]: To provide a compound having a novel structure effective againstand erythromycin resistant bacteria (for example, resistant pneumococci and streptococci) as well as against conventional erythromycin sensitive bacteria. [Solution]: A novel 10a-azalide compound represented by the formula (I), a pharmaceutically acceptable salt thereof or a solvate thereof, or an intermediate for the preparation of the same. The compound of the present invention has superior antibacterial activity against, erythromycin resistant pneumococci and the like, and therefore, the compound can be used as a therapeutic agent of infectious diseases.

10a-Azalide compound

Growing community of inventors

Saitama, Japan

Tomohiro Ozawa